Sam Fazeli

So things have clearly gone in the right direction and very well for Antoine.

Welcome, Antoine.

It's really nice to have you with us.

Yeah.

I mean, you can't not be an optimist when you work in biotech, right?

Because it's feast and famine at times.

And also, you need that, I think, in order to see through the risks and look at the potential.

And of course, you do capital management in a sensible way to try and get the risks taken care of as much as possible.

But that is what biotech is.

And I have to say that I think Antoine is one of the most

optimistic people that I remember sitting on panels with, etc.

So it always was a pleasure to have those conversations.

We didn't always agree, but I think a lot of it was more for making the panels more interesting.

So where does Sofinova sit in the venture community in terms of approach?

What is special, if anything, about the group and in terms of the way you look at things?

Right, so when I look at these, Sophronova Capital is, for me at least, easy to understand.

I know what the idea is, biotech companies mostly, right?

Medical devices, I get that too.

Crossover, yeah, I get that.

We can talk about that in a minute, how the environment is for that particular area.